KIDS
OrthoPediatrics Corp.
KIDS's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over KIDS overall, supported by stronger modeled upside and stronger valuation.
KIDS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Stable | |
| Unavailable |
KIDS's revenue is currently healthy, and its cash flow is stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KIDS PE Valuation
KIDS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
KIDS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect KIDS's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
KIDS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.43 | +$0.53 |
| Q2 2026 | -$1.68 | +$0.12 |
| Q1 2026 | -$1.68 | +$0.08 |
| Q4 2025 | -$1.69 | -$0.05 |
| Q3 2025 | -$1.96 | -$0.73 |
| Q2 2025 | -$1.80 | -$0.71 |
| Q1 2025 | -$1.76 | -$0.80 |
| Q4 2024 | -$1.64 | -$0.72 |
KIDS is still losing money, but less than at its worst: $1.43 per share over the past year, against $2.05 at its worst in early 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over KIDS on earnings quality, reporting a profit while its opponent remains loss making.
KIDS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72.7M | +19% |
| Q2 2026 | $70.5M | +15% |
| Q1 2026 | $59.4M | +13% |
| Q4 2025 | $61.6M | +17% |
| Q3 2025 | $61.3M | +12% |
| Q2 2025 | $61.1M | +16% |
| Q1 2025 | $52.4M | +17% |
| Q4 2024 | $52.7M | +40% |
KIDS's revenue has grown year over year for 23 quarters in a row: $73M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.8% | +9.6 points |
| Q2 2026 | -5.8% | +12 points |
| Q1 2026 | -14% | +6.9 points |
| Q4 2025 | -13% | +13 points |
| Q3 2025 | -15% | -5.2 points |
| Q2 2025 | -17% | -6.7 points |
| Q1 2025 | -21% | +0.8 points |
| Q4 2024 | -27% | -5.3 points |
KIDS's operating margin was −5.8% last quarter, up 9.6 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over KIDS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over KIDS on profitability, with a higher operating margin.
KIDS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6M | +$5M |
| Q2 2026 | -$3.1M | +$10.8M |
| Q1 2026 | -$5M | +$3.3M |
| Q4 2025 | $9.7M | +$13.5M |
| Q3 2025 | -$3.4M | +$8.2M |
| Q2 2025 | -$13.9M | -$1.1M |
| Q1 2025 | -$8.4M | +$4.8M |
| Q4 2024 | -$3.7M | +$7.7M |
KIDS has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
KIDS Net Leverage
KIDS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KIDS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.2 | Overbought |
| Stochastic | 84.8 | Overbought |
KIDS's weekly RSI is 78 (overbought) and its Stochastic is 85 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KIDS PE vs Healthcare Sector
| Metric | KIDS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KIDS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
KIDS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.0 | 25% above |
| 20 week MA | $23.5 | 39% above |
| 50 week MA | $19.9 | 64% above |
| 100 week MA | $20.6 | 58% above |
| 200 week MA | $27.3 | 19% above |
KIDS has climbed back above all five of its weekly moving averages, and it's now 19% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
KIDS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.5 | $46.3 | -0.4% |
| 2021 | $46.3 | $60.8 | +31% |
| 2022 | $60.8 | $38.0 | -37% |
| 2023 | $38.0 | $32.5 | -14% |
| 2024 | $32.5 | $22.9 | -30% |
| 2025 | $22.9 | $17.3 | -24% |
| 2026 YTD | $17.3 | $32.6 | +88% |
KIDS has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.